期刊文献+

头花蓼对幽门螺杆菌相关性胃炎大鼠胃组织SIRT1、p53和p21的影响 被引量:5

Effects of Polygonum capitatum on SIRT1,p53 and p21 in Helicobacter Pylori Associated Gastritis Rats
下载PDF
导出
摘要 目的:观察头花蓼对幽门螺杆菌相关性胃炎(HAG)的治疗效果及对HAG胃组织中SIRT1/p53/p21信号通路的影响。方法:30只SD大鼠均分为正常对照组、模型组和药物组,正常对照组给予无菌脑心浸液肉汤灌胃,模型组和药物组大鼠给予H.pylori灌胃(1×1011CFU/L SS2000菌液1.5 m L/只)建立HAG模型,药物组HAG模型大鼠给予1.58 mg/(kg·d)头花蓼灌胃治疗,正常对照组大鼠和模型组大鼠给予等量无菌生理盐水灌胃,连续给药14 d;治疗结束4周时检测大鼠胃组织H.pylori定植量、观察各组大鼠胃黏膜组织学改变,采用Real time PCR和Western blot技术检测大鼠胃组织SIRT1、p53及p21 mRNA及蛋白表达水平。结果:正常对照组大鼠胃组织H.pylori定植量为0,模型组和药物组大鼠胃黏膜均有H.pylori定植,与模型组比较,药物组H.pylori定植量显著降低(P<0.05);正常对照组大鼠胃组织无病理形态学改变,模型组大鼠H.pylori感染后的胃黏膜腺体排列不规则,胃黏膜固有层中有较多淋巴细胞浸润,细胞浸润多呈弥漫性;药物组大鼠胃组织病理形态学改变少于模型组;与正常对照组比较,模型组病理评分显著升高,而药物组病理评分显著低于模型组,差异有统计学意义(P<0.05);H.pylori感染后,与正常对照组相比,模型组大鼠胃组织SIRT1、p53基p21 mRNA表达量增加(P<0.05);头花蓼治疗后,与模型组相比,药物组大鼠胃组织SIRT1、p53及p21 mRNA水平都明显升高(P<0.05);与正常对照组相比,模型组大鼠胃组织SIRT1、p53及p21蛋白表达均有所升高,但差异无统计学意义(P>0.05);而头花蓼治疗后,与模型组相比,SIRT1、p53和p21蛋白表达明显升高(P<0.05)。结论:头花蓼治疗可能是通过上调SIRT1、p53和p21基因表达来发挥作用。 Objective: To observe the antibacteria function of Polygonum capitatum in Helicobacter pylori-associated gastritis( HAG),and to investigate whether SIRT1/p53/p21 signal pathway was influenced. Methods: Thirty rats were randomly divided into normal control group( NC),model control group( MC) and drug treatment group( DT). Rats in group NC were given gavage of sterile brain heart infusion broth,and those of groups MC and DT were given with H. pylori( 1 × 1011 cfu/L,1. 5 m L each rat) to establish HAG model. Rats in group DT were then given P. capitatum 1. 58 mg/( kg·d) for treatment,while rats in groups NC and MC were given sterile normal saline for two weeks. In 4 weeks after the treatment finished,the levels of H. pylori colonization in gastric mucosa were detected and the pathological changes in gastric mucosa were observed with HE stained sections.The expression of SIRT1,p53,p21 mRNA and proteins were determined by real-time PCR and western blotting. Results: The colonization quantity of H. pylori in gastric mucosa of group NC was 0. The H. pylori level in group DT was significantly lower than that in group MC( P 〈0. 05). No pathological change was found in rats of group NC. In rats of group MC,after H. pylori infection,the gastric mucosa glands arranged irregularly,and there were relatively more lymphocytes diffusively infiltrated in gastric mucosa lamina propria. In group DT,the pathological scores were significantly lower than those in group MC( P〈 0. 05).,The expression levels of rat gastric tissue SIRT1,p53 and p21 mRNA were higher in group MC than those in group NC( P 〈0. 05) after H. pylori infection,and were obviously higher in group DT than those in group MC( P 〈0. 05) after treatment with P. capitatum. The expression of SIRT1,p53 and p21 protein in group MC was higher than that in group NC,but the difference was not significant( P 〉0. 05),and it's obviously higher in group DT than in group MC. Conclusions:P. capitatum has some curing effects to HAG,which might perform through the signal pathway of SIRT1/p53/p21 by up regulating expression of SIRT1/p53/p21 genes.
作者 吴琼 莫非 孙朝琴 罗昭逊 张姝 张梦薇 江明礼 WU Qiong, MO Fei, SUN Chaoqin, LUO Zhaoxun, ZHANG Shu, ZHANG Mengwei, JIANG Mingli(School of Clinical Laboratory Science, Guizhou Medical University, Guiyang 550004, Guizhou, Chin)
出处 《贵州医科大学学报》 CAS 2018年第3期279-284,共6页 Journal of Guizhou Medical University
基金 贵州省科技合作计划基金[黔科合LH(2015)7417号] 贵州省卫生计生委科学技术基金(gzwikj2015-1-003) 贵阳市科技计划项目[筑科合同(2014001)] 贵州省中医药管理局中医药、民族医药科学技术研究项目(QZYY-2016-005)
关键词 头花蓼 幽门螺杆菌 幽门螺杆菌相关性胃炎 SIRT1/p53/p21信号通路 模型 动物 大鼠 Spra-gue Dawley Polygonum capitatum Helicobacter pylori Helicobacter pylori associated gastritis SIRT1/p53/p21 signal pathway model, animal rats, Sprague Dawley
  • 相关文献

参考文献5

二级参考文献38

  • 1李妍,宁云山,龙敏,董文其,李明.幽门螺杆菌Catalase基因的克隆、表达及其抗原性鉴定[J].细胞与分子免疫学杂志,2006,22(4):440-442. 被引量:6
  • 2常栋,王天佑,魏锦昌,宋金祥,焦广根.原发性食管腺癌的外科治疗[J].中华外科杂志,2007,45(10):681-683. 被引量:11
  • 3[4]ww.fda.gov/cder/cancer/animalframe.htm
  • 4[5]FDA Guidance for industry and reviewers: Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers[ S]. 2002; 12
  • 5[6]FDA Guidance for Industry: food-effect bioavailability and fed bioequivalence studies[ S]. 2002; 12
  • 6Deng B, Li Y, Zhang Y, et al. Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis[J]. Car- cinogenesis, 2013,34(6) : 1189-1195.
  • 7Sutton P, Chionh YT. Why can't we make an effective vaccine against Helicobacter pyloriy [J]. Expert Rev Vaccines, 2013, 12(4) :433-441.
  • 8Peek RM Jr,Blaser MJ. Helicobacter pylori and gastrointesti- nal tract adenocarcinomas[J]. Nat Rev Cancer,2002,2(1 ) :28- 37.
  • 9理查德J.辛普森蛋白质与蛋白质组学实验指南[M].北京:化学工业出版社,2006,131-200.
  • 10Stent A,Every AL, Sutton P. Helicobacter pylori defense a gainst oxidative attack[J]. Am J Physiol Gastrointest Liver Physiol,2012,302(6) : G579-587.

共引文献1435

同被引文献64

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部